Eli Lilly and Company (LLY) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Eli Lilly and Company (NYSE: LLY):

• 9/15/2026 – Eli Lilly and Company was given a new $1,400.00 price target by Berenberg Bank. They now have a “buy” rating on the stock.
• 9/15/2026 – Eli Lilly and Company was upgraded by Berenberg Bank from “hold” to “buy”. They now have a $1,400.00 price target on the stock.
• 9/10/2026 – Eli Lilly and Company had its price target raised by HSBC Holdings plc from $850.00 to $940.00. They now have a “reduce” rating on the stock.
• 9/9/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/1/2026 – Eli Lilly and Company was upgraded by BMO Capital Markets from “outperform” to “buy”.
• 8/26/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/23/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/15/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 8/11/2026 – Eli Lilly and Company was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 8/7/2026 – Eli Lilly and Company was given a new $1,376.00 price target by UBS Group AG.
• 8/7/2026 – Eli Lilly and Company had its price target raised by Truist Financial Corporation from $1,370.00 to $1,376.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $1,419.00 price target on the stock.
• 8/6/2026 – Eli Lilly and Company had its price target raised by Wells Fargo & Company from $1,280.00 to $1,330.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $1,400.00 price target on the stock.
• 8/6/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,350.00 to $1,410.00. They now have an “overweight” rating on the stock.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 23.22%.

Insiders Place Their Bets

In other news, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 over the last 90 days. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.